Leadership Team

Dr Keith Wilson

VP CMC & Manufacturing

Dr Keith Wilson

Keith joined AMAL in 2020 and is now leading the CMC & Manufacturing team.

Keith has a PhD in Biochemical Immunology with more than 20 years of experience in Biopharmaceutical R&D with managerial experience in drug development. After 2 years post-doctoral studies, Keith’s  initial experience was in Analytical Sciences at GSK Biopharmaceutical Development in the UK. Subsequently, he moved to Lonza Biologics to head up the Analytical Method Development team and then as Technical Director.

Keith moved to Geneva in 2014 to join Novimmune as Head of Bioprocess R&D and led the CMC development and subsequent initial commercial manufacturing of Gamifant (emapalumab-lzsg) as well as the development of a number of other monoclonal and bi-specific antibodies. Keith joins AMAL from Swedish Orphan Biovitrum, who acquired Gamifant and related assets in July 2019.

back to Leadership Team

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: